The FDA has launched a nationwide recall of children’s ibuprofen affecting nearly 90,000 bottles due to contamination concerns.
The recall involves children’s ibuprofen oral suspension, USP, 100 milligrams per 5 milliters, 4-fluid ounce or 120-milliter bottles manufactured for Taro Pharmaceuticals U.S.A., according to a March 16 FDA enforcement report.
Strides Pharma recalled 89,592 bottles after receiving complaints of a gel-like mass and black particles in the product. The affected lots are 7261973A and 7261974A, with an expiration date of Jan. 31, 2027.
The recall was initiated March 2 and remains ongoing, with products distributed nationwide.
The FDA designated the event as a Class II recall, meaning exposure may cause temporary or medically reversible adverse health consequences with a low risk of serious harm.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
